Literature DB >> 10429138

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

J Biederman1, T Wilens, E Mick, T Spencer, S V Faraone.   

Abstract

OBJECTIVE: To assess the risk for substance use disorders (SUD) associated with previous exposure to psychotropic medication in a longitudinal study of boys with attention-deficit/hyperactivity disorder (ADHD).
METHODS: The cumulative incidence of SUD throughout adolescence was compared in 56 medicated subjects with ADHD, 19 nonmedicated subjects with ADHD, and 137 non-ADHD control subjects.
RESULTS: Unmedicated subjects with ADHD were at a significantly increased risk for any SUD at follow-up compared with non-ADHD control subjects (adjusted OR: 6.3 [1.8-21.6]). Subjects with ADHD medicated at baseline were at a significantly reduced risk for a SUD at follow-up relative to untreated subjects with ADHD (adjusted OR: 0.15 [0.04-0.6]). For each SUD subtype studied, the direction of the effect of exposure to pharmacotherapy was similar to that seen for the any SUD category.
CONCLUSIONS: Consistent with findings in untreated ADHD in adults, untreated ADHD was a significant risk factor for SUD in adolescence. In contrast, pharmacotherapy was associated with an 85% reduction in risk for SUD in ADHD youth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10429138     DOI: 10.1542/peds.104.2.e20

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  87 in total

Review 1.  Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability.

Authors:  R Andrew Chambers; Jane R Taylor; Marc N Potenza
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

2.  Bupropion for adults with attention deficit hyperactivity disorder.

Authors:  Jeffery H Newcorn
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

3.  Foreword -- ADHD in the scientific and political context.

Authors:  Jan K Buitelaar; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

4.  Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains.

Authors:  Pamela B Yang; Alan C Swann; Nachum Dafny
Journal:  Brain Res Bull       Date:  2006-10-19       Impact factor: 4.077

5.  Cardiac risk assessment before the use of stimulant medications in children and youth.

Authors:  S A Bélanger; A E Warren; R M Hamilton; C Gray; R M Gow; S Sanatani; J M Côté; J Lougheed Frcpc; J Leblanc; S Martin; B Miles; C Mitchell; D A Gorman; M Weiss; R Schachar
Journal:  Paediatr Child Health       Date:  2009-11       Impact factor: 2.253

6.  Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Authors:  Chloe J Jordan; Roxann C Harvey; Britahny B Baskin; Linda P Dwoskin; Kathleen M Kantak
Journal:  Drug Alcohol Depend       Date:  2014-04-28       Impact factor: 4.492

7.  Stimulant treatment of ADHD and cigarette smoking: a meta-analysis.

Authors:  Erin N Schoenfelder; Stephen V Faraone; Scott H Kollins
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

Review 8.  Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment.

Authors:  Duncan B Clark; Oscar Bukstein; Jack Cornelius
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.